CART-Related Neurotoxicity Pipeline: Advancing Therapeutic Strategies and Clinical Research
Overview of CART-Related Neurotoxicity Chimeric antigen receptor T-cell (CAR-T) therapy has significantly transformed cancer treatment, particularly for patients with relapsed or refractory B-cell lymphomas, acute lymphoblastic leukemia, and multiple myeloma. This innovative immunotherapy involves genetically engineering a patient's T cells to recognize and destroy malignant cells, delivering meaningful clinical responses in several hematological cancers. Despite its therapeutic effectiveness, CAR-T treatment can cause serious adverse events, including immune effector cell-associated neurotoxicity syndrome (ICANS) and other neurological complications. The expanding adoption of cellular immunotherapies has increased attention toward the cart-related neurotoxicity market , as pharmaceutical developers and researchers investigate approaches to prevent, identify, and manage treatment-associated neurological toxicities. Clinical manifestations range from headaches, confusion, tremors,...